(2-8 mg/day). Doxazosin was recently withdrawn from this trial after an interim analysis showed the secondary end point of combined cardiovascular disease to be 25% greater in patients on ...

In this regard, 4-years into the study, 40% and 47% of the chlorthalidone and the doxazosin treatment groups were receiving step 2 and/or 3 medications ... was capped at 8 mg in this study.